Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to